(NASDAQ: GOSS) Gossamer Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.8%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.78%.
Gossamer Bio's earnings in 2026 is -$125,223,000.On average, 9 Wall Street analysts forecast GOSS's earnings for 2026 to be -$100,129,863, with the lowest GOSS earnings forecast at -$138,211,633, and the highest GOSS earnings forecast at -$62,557,104. On average, 9 Wall Street analysts forecast GOSS's earnings for 2027 to be -$47,254,979, with the lowest GOSS earnings forecast at -$143,601,168, and the highest GOSS earnings forecast at -$17,387,667.
In 2028, GOSS is forecast to generate -$54,857,768 in earnings, with the lowest earnings forecast at -$225,162,799 and the highest earnings forecast at -$5,261,213.